About SAB Biotherapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.sab.bio/
Frequently Asked Questions
What is the 52-week range for SABS?
The 52-week high is $5.15 and the 52-week low is $1.9085.
What is the P/E ratio for SABS?
The Price to Earnings (P/E) ratio is 20.98.
What is the dividend yield for SABS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 15.17%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1795.85%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.18.
Analyst Recommendation Trends
Wall Street analyst consensus for SABS over the last few months:
Latest SABS News
SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
Presentations will feature encore Phase 1 data highlighting the mechanism of action, redosing potential, and early C-peptide response associated with SAB-142, a fully human multi-specific ATG for Stage 3 type 1 diabetesMIAMI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) being held September 28 - October 2, 2026 in Milan, Italy. Presented data will highlight SAB BIO’s lead program, SAB-142, a pot
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SAB Biotherapeutics, Inc. (SABS) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 11:20 AM EDTCompany ParticipantsSamuel Reich - CEO...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-17 | Kropotova Alexandra | -473 | - | - |
| 2026-06-25 | Kropotova Alexandra | -988 | - | - |
| 2026-03-24 | Kropotova Alexandra | -988 | - | - |
| 2026-02-03 | Sullivan Eddie Joe | +3,000,000 | - | - |
| 2026-02-03 | Bausch Christoph Lawrence | +1,800,000 | - | - |
| 2026-02-03 | To Lucy | +2,400,000 | - | - |
| 2026-02-03 | Kropotova Alexandra | +2,400,000 | - | - |
| 2026-02-03 | Reich Samuel J | +4,800,000 | - | - |
| 2026-01-05 | Jain Rita | +240,000 | - | - |
| 2026-01-05 | ZACCARDELLI DAVID | +240,000 | - | - |
| 2025-12-16 | Polvino William James | +150,000 | - | - |
| 2025-12-16 | Ellias Helen K. | +150,000 | - | - |
| 2025-12-16 | Giberson Scott | +150,000 | - | - |
| 2025-12-16 | Link David | +150,000 | - | - |
| 2025-12-16 | Lucera Erick | +150,000 | - | - |
| 2025-12-16 | SKYLER JAY S | +150,000 | - | - |
| 2025-12-11 | Kropotova Alexandra | -988 | - | - |